201 related articles for article (PubMed ID: 31179561)
1. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
[No Abstract] [Full Text] [Related]
2. From Metcalf to myeloproliferative neoplasms - a personal journey.
Green T
Exp Hematol; 2022 Jan; 105():2-9. PubMed ID: 34706253
[TBL] [Abstract][Full Text] [Related]
3. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
Struski S; Luquet I
Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
[No Abstract] [Full Text] [Related]
4. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
[TBL] [Abstract][Full Text] [Related]
5. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
Northrup V; Maybank A; Carson N; Rahmeh T
Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
[TBL] [Abstract][Full Text] [Related]
6. Speaking a common language in MDS/MPNs.
Steensma DP
Blood; 2015 Mar; 125(12):1849-51. PubMed ID: 25792730
[TBL] [Abstract][Full Text] [Related]
7. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.
Iurlo A; Gianelli U; Cattaneo D; Thiele J; Orazi A
Am J Hematol; 2017 Apr; 92(4):E48-E51. PubMed ID: 28109016
[No Abstract] [Full Text] [Related]
9. Issue Highlights - July 2019.
Cytometry B Clin Cytom; 2019 Jul; 96(4):253-255. PubMed ID: 31321907
[No Abstract] [Full Text] [Related]
10. Preface.
Verstovsek S
Best Pract Res Clin Haematol; 2014 Jun; 27(2):81-2. PubMed ID: 25189719
[No Abstract] [Full Text] [Related]
11. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
12. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, staging and prognostic factors.
Schouten HC
Ann Oncol; 2007 Jan; 18 Suppl 1():i22-i28. PubMed ID: 17311817
[No Abstract] [Full Text] [Related]
14. [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].
Kubuki Y; Hidaka T; Shimoda K
Rinsho Ketsueki; 2015 Oct; 56(10):1996-2004. PubMed ID: 26458438
[TBL] [Abstract][Full Text] [Related]
15. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
16. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
17. Preface.
Michaelis LC
Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
[No Abstract] [Full Text] [Related]
18. Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms.
Herlihy N; Harrison CN; McLornan DP
Haematologica; 2019 Apr; 104(4):639-641. PubMed ID: 30930333
[No Abstract] [Full Text] [Related]
19. Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Hueso T; Johnson-Ansah H; Decamp M; Maitre E; Henry A; Mensi S; Vilque JP; Chantepie S; Damaj G
Curr Res Transl Med; 2019 Nov; 67(4):149-151. PubMed ID: 31153956
[No Abstract] [Full Text] [Related]
20. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
Pemmaraju N; Kantarjian H; Nastoupil L; Dupuis M; Zhou L; Pierce S; Patel KP; Masarova L; Cortes J; Verstovsek S
Blood; 2019 May; 133(21):2348-2351. PubMed ID: 30796023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
